Delphi advises Immunicum in the acquisition of DCprime
Delphi has advised Immunicum AB (publ) in connection with the company entering an agreement to acquire all of the shares in DCprime B.V., a Dutch oncology vaccine company. By way of the transaction, Immunicum acquires all shares in DCprime through the issuance of shares to DCprime’s majority shareholder Van Herk Investments B.V.
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. The company’s goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. Immunicum’s shares are listed on Nasdaq Stockholm.